Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today an update regarding the Company's diverse oncology portfolio, including the acceptance of a wide...

Results from a Phase 2 randomized, multi-center clinical trial in pancreas cancer patients conducted by Halozyme Therapeutics (NASDAQ: HALO) of its targeted investigational therapy, PEGPH20, will...

Bayer announced today that the latest research from across its growing oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of two abstracts at the 2017 American Society of...

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and development targeted kinase medicines for patients with genomically defined diseases, today announced that new data from...